TWiV 131: A REOstat for cancer

May 1, 2011

reovirus coreHosts: Vincent Racaniello, Alan Dove, Dickson Despommier, and Brad Thompson

Vincent, Alan, and Dickson chat with Brad Thompson, CEO of Oncolytics Biotech, about using reovirus to treat cancer.

Play

Click the arrow above to play, or right-click to download TWiV #131 (42 MB .mp3, 97 minutes).

Subscribe to TWiV (free) in iTunes , at the Zune Marketplace, by the RSS feed, by email, or listen on your mobile device with the Microbeworld app.

Links for this episode:

Weekly Science Picks

Dickson – Angels and Insects
Alan – Science Buddies
Vincent – Emerging Diseases: The Importance of Early Warning and Surveillance (YouTube)

Listener Pick of the Week

Josh  - Prof. Racaniello’s Virology course on iTunes

Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv, or call them in to 908-312-0760. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twiv.

  • Komal

    Can reovirus therapy also be effective against hematologic cancers, like leukemias, or would it only work for solid tumors?

  • http://www.virology.ws profvrr

    I asked Brad Thompson and he replied: Reo works well in the lab
    against leukemias. We are discussing with the NCI a request by them to
    run a REO study on leukemia.

  • matt

     A little behind on my listening but this is a fantastic podcast this week.  Hearing the tale of the oncolytic Reo story was great.  And hearing it from someone who has been on both sides of the bench and boardroom is pretty cool.  Keep it up!

  • vladimir

    Very interesting,  I am currently taking virology with Dr. Isern at FGCU and listening to the TWiV really helps me in the class.

  • http://www.virology.ws profvrr

    Glad that TWiV helps! We did a live TWiV at FGCU last year – see TWiV #111. 

  • Pingback: TWiV 164: Six steps forward, four steps back

  • Jon

    This episode was really interesting.  Any plans to interview some of the proponents of other Oncolytic viruses?  (Maybe someone from Jennerex, for example.)  As a layman, I’m curious to know if the several oncolytic viruses under development complement or compete with each other.

  • Jon

    Update: In Dec 2012 Oncolytics has released some preliminary data, with statistical significance (p=.03) for shrinking metastatic tumors at 6-weeks into treatment. The gold-standard effect on overall survival will not be available until the data matures sometime in 2013.

  • B Chin

    Indeed, it appears that the NCI is going to sponsor a myeloma trial: http://bit.ly/1iEqFbp (Thank god national cancer institutes funding, which is out of the purview of wall street fickleness.)